Standard BioTools Net Income

Standard BioTools (LAB) currently reports a net income of $78M as of March 2026. That compares with $-130M in the prior-year period — up 158.9% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Standard BioTools's net income history and peer comparisons.

Standard BioTools's net income increased from $-130M to $78M — a 158.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Standard BioTools's net income of $78M is lower than the Healthcare sector average of $16B. That is roughly 99.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Standard BioTools reported $78M in net income as of March 2026. That compares with $-130M in the prior-year period — up 158.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $78M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Standard BioTools, and consider following LAB for alerts when major investors trade the stock.